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terol is degraded into bile acids, and the rate-limitingAjay Chawla, Enrique Saez, and Ronald M. Evans*
Howard Hughes Medical Institute step for the neutral bile biosynthesis pathway is cata-
The Salk Institute for Biological Sciences lyzed by the cytochrome P450 cholesterol 7a-hydroxy-
10010 N. Torrey Pines Road lase or CYP7A1 (Russell and Setchell, 1992). Regulation
La Jolla, California 92037 of CYP7A1 levels is known to occur primarily at the
transcriptional level and is modulated by the relative
ratio of cholesterol to bile acids in the liver. A minireview
describing the pathways of cholesterol catabolism andA central aspect of lipid homeostasis in vertebrates is
their regulation by nuclear receptors was published lastthe acquisition, synthesis, and metabolism of choles-
year in Cell (Russell, 1999). Here, we review work pub-terol. As mediators of organ physiology, nuclear hor-
lished recently in Cell and Molecular Cell that establishesmone receptors and other proteins such as the SREBPs
a specific role for the nuclear receptor FXR in this pro-are believed to play a key role in these processes by
cess and in the repression of the CYP7A1 gene. Thiscontrolling the transcription of genes encoding apolipo-
work enhances our understanding of how cholesterolproteins, transporters, as well as synthetic and catabolic
catabolism is regulated by nuclear receptors, and thusenzymes (Brown and Goldstein, 1997). Since their initial
has important implications for future drug developmentdiscovery, orphan nuclear receptors have been sus-
in the treatment of hypercholesterolemia and chole-pected to represent critical components of lipid metabo-
stasis.lism; however, deciphering their precise roles has repre-
Role of FXR in Bile Acid Homeostasissented a major challenge (Blumberg and Evans, 1998;
The metabolic regulation of CYP7A1 has been an activeGiguere et al., 1988). Particularly vexing is understand-
area of research for decades because of its role in cho-ing the molecular links that make physiology integrative.
lesterol metabolism (Russell and Setchell, 1992). TwoThe liver is the central organ for regulation of choles-
papers in the September issue of Molecular Cell useterol homeostasis. Integrating pathways of synthesis
different approaches to shed light on how bile acidsand degradation, it provides cells with the cholesterol
repress the transcription of the CYP7A1 gene, the rate-needed for cellular growth, while preventing its patho-
logic accumulation. The majority of any excess choles- limiting step in their synthesis (Goodwin et al., 2000; Lu
Figure 1. Cascades of Nuclear Receptors
Regulate Cholesterol and Bile Acid Absorp-
tion and Degradation
Enterocyte. Dietary cholesterol (Ch) is solubi-
lized by the action of bile acids (BA) and taken
by enterocytes. Inside, high cholesterol levels
induce the formation of oxysterols (Ox) that
activate LXR, which promotes cholesterol ef-
flux into the intestinal lumen via the ABCA1
transporter. Bile acids enter the enterocyte
through the I-BAT transporter and activate
FXR, which upregulates the levels of I-BABP.
FXR may also control the expression of a hy-
pothetical intestinal bile acid transporter that
exports bile salts into the bloodstream.
Hepatocyte. Circulating bile acids are extrac-
ted from portal blood by the hepatic basolat-
eral transporter NTCP. Increasing concen-
trations of bile acids inside the hepatocyte
activate FXR. This bile acid sensor modulates
further bile acid uptake by decreasing the
levels of NTCP, and increasing those of
BSEP. FXR also induces expression of SHP,
a nuclear receptor that suppresses bile acid
synthesis by antagonizing the function of
LRH-1, an orphan receptor required for ex-
pression of CYP7A1. Cholesterol-carrying
particles are taken into the liver via the LDL and scavenger receptors, such as SR-B1. Increased hepatic cholesterol levels lead to suppression
of endogenous synthesis and downregulation of the LDL receptor, processes which are mediated by the SREBPs. LXR promotes conversion
of surplus cholesterol into bile acids by increasing the levels of CYP7A1 expression. BSEP then exports newly synthesized bile acids for
secretion into the intestine.
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et al., 2000). Both groups identify the orphan nuclear develop hepatotoxicity from excess accumulation of bile
salts. The knockout mice have dramatic increases inreceptor SHP (small heterodimer partner) as a direct
transcriptional target of FXR and bile acids. In turn SHP serum levels of bile acids, which are secondary to im-
paired bile acid secretion from the liver and decreasedthen antagonizes LRH-1 (liver receptor homolog-1),
another orphan nuclear receptor that stimulates the excretion of bile salts into the feces. Associated with
these pathologic changes are alterations in the expres-CYP7A1 promoter. This molecular titration allows bile
acid synthesis to be linked to bile acid levels (Figure 1). sion of genes involved in bile acid secretion, transport,
and synthesis. For example, FXR null mice exhibit a 20-Since small lipophilic molecules function as molecular
switches for the activation of nuclear receptors, these fold reduction in the expression of the bile salt export
pump (BSEP). BSEP, a member of the ABC family oftranscription factors lend themselves to chemical geno-
mic analysis. Goodwin et al. employ combinatorial chem- transporters, exports bile salts from the liver into the
biliary tree for excretion into the intestinal lumen (Baharistry and gene expression profiling to explore the role
of FXR in gene regulation. The authors screened combi- and Stolz, 1999). Similarly, expression of ileal bile acid
binding protein (I-BABP) is absent in the FXR null mice.natorial chemical libraries in a fluorescence-based, pep-
tide binding assay to identify the isoxazole compound Although the precise function of I-BABP in enterocytes
is unknown, it is believed that it facilitates intracellularGW4064 as a high-affinity FXR agonist. Gene expression
profiling was subsequently performed on RNA from liv- transport of bile salts and protects enterocytes from the
detergent effects of bile acids (Bahar and Stolz, 1999).ers of animals that had been treated with this agonist.
These analyses elegantly revealed a striking reciprocal On the other hand, bile acid biosynthetic genes CYP7A1
and CYP8B1, which are normally repressed by bilerelationship between the expression of CYP7A1 and the
orphan nuclear receptor SHP, suggesting that SHP acids, are not downregulated in FXR2/2 mice fed 1%
cholic acid. These findings clearly establish that bilemight modulate the expression of CYP7A1. Indeed, the
authors show that SHP, which lacks a DNA binding do- acids are natural ligands for FXR, and demonstrate that
FXR is a key regulator of bile acid homeostasis.main, represses CYP7A1 indirectly by binding the or-
phan nuclear receptor LRH-1 and antagonizing its tran- Transcriptional Control of CYP7A1
In 1992, based on the results of nuclear run-on experi-scriptional activity on the CYP7A1 promoter.
In the companion article by Lu et al., a more directed ments, Russell and Setchell proposed a model for the
transcriptional control of the CYP7A1 gene (Russell andapproach leads to a similar conclusion. These authors
elaborate on their previous work and that of Nitta et al. Setchell, 1992). They suggested that the CYP7A1 pro-
moter must contain both a positive sterol response ele-to show that LRH-1 works as a competence factor on
the CYP7A1 promoter, both establishing the basal level ment that transcriptionally activates the gene in re-
sponse to dietary cholesterol, and a negative bile acidof expression as well as participating in LXR-induced
expression of this gene (Nitta et al., 1999). Since LRH-1 response element that represses transcription in re-
sponse to bile acids. Almost a decade later, it appearsis a close relative of the orphan receptor steroidogenic
factor-1 (SF-1), these authors hypothesized that the that CYP7A1 regulation is controlled by a set of five
orphan nuclear receptors (RXR, FXR, LXR, SHP, andtranscriptional activity of LRH-1 might be modulated in
a manner analogous to that of SF-1 (Parker et al., 1999). LRH-1), whose interactions largely support the original
model of Russell and Setchell (Figure 1). First, the tissue-DAX1, an atypical orphan nuclear receptor, interacts
with SF-1 to inhibit the expression of SF-1 target genes. specific and normal expression levels of CYP7A1 are
probably regulated by LRH-1, although confirmation willSince SHP is the closest homolog of DAX1 and has also
been shown to inhibit receptor transactivation, these have to await the generation of LRH-1 knockout mice
(Nitta et al., 1999). In this view LRH-1 is key to establish-authors asked whether SHP acts as an inhibitor of the
CYP7A1 gene (Seol et al., 1996). Indeed, they show that ing a physiologic “set-point” for CYP7A1. Second, the
sterol induction of CYP7A1 is mediated by the RXR/SHP interacts with LRH-1 and turns off CYP7A1 expres-
sion. This regulatory loop is completed by the identifica- LXRa heterodimer. Accordingly, mice that are homozy-
gous null for the LXRa gene or selectively deficient oftion of an FXR response element in the promoter of SHP.
Collectively, these two papers explain how bile acids or the hepatic RXRa gene are unable to upregulate CYP7A1
in response to increased dietary cholesterol (Peet et al.,FXR activators can indirectly repress target gene ex-
pression, answering a long standing question as to how 1998; Wan et al., 2000). Third, the negative regulation
of CYP7A1 by bile acids is indirectly mediated by thebile acids feed back to transcriptionally repress their
own synthesis. bile acid receptor FXR also as an RXR heterodimer. As
discussed above, FXR null mice are unable to repressDoes FXR actually participate in bile acid homeosta-
sis, and does it function as the bile acid receptor in the CYP7A1 gene in response to a 1% cholic acid diet.
Taken together, these findings suggest a model in whichvivo? The paper by Sinal et al. describes the targeted
disruption of the FXR gene in mice establishing a pivotal the basal expression of CYP7A1 is primarily controlled
by one or more liver-specific transcription factors, suchrole of this nuclear receptor in bile acid homeostasis
(Sinal et al., 2000). FXR null mice are healthy and fertile as LRH-1, wherein positive and negative regulation is
mediated by LXRa and FXR, respectively. In support ofunder standard laboratory conditions, presumably due
to basal expression of CYP7A1. However, upon dietary this model, the basal expression of CYP7A1 is essen-
tially unchanged in both the LXRa and FXR null micechallenge with cholic acid, an FXR ligand, mutant mice
become gravely ill and demonstrate an impaired ability under standard dietary conditions.
Do the FXR knockout mice provide genetic evidenceto deal with an excess load of dietary bile acids. When
placed on a 1% cholic acid diet for 5 days, null animals to support the proposed mechanism for repression of
CYP7A1 by bile acids? As predicted by the two Molecu-rapidly lose adipose tissue and body weight, and later
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lar Cell papers, SHP expression is reduced in FXR null cascade regulates other pathways in kidney and adrenal
gland will be important.mice by 5-fold on a control diet and by about 15-fold
Nuclear Receptors, Cholesterol Homeostasis,in mice fed a 1% cholic acid diet as compared to wild-
and Therapeutic Implicationstype mice placed on similar diets. The lack of induction
The work discussed above and an additional paperof SHP in response to bile acids correlates well with the
strengthen the notion that nuclear receptors are keylack of repression of both the CYP7A1 and CYP8B1
regulators of cholesterol catabolism. The paper by Repagenes in the FXR null mice. Although these studies con-
et al. links RXRs and LXRs to pathways of cholesterolfirm that SHP is a target of FXR and bile acids, additional
absorption and efflux (Repa et al., 2000). These authorsstudies with transgenic animals overexpressing SHP or
found that treatment of mice with the RXR ligand, LG268,animals with deletion of the SHP gene will be needed
results in potent inhibition of cholesterol absorption. Ato establish whether SHP is the sole mediator of the
decrease in bile acid pool size and an induction ofrepressive activity of bile acids.
ABCA1, an ABC family transporter that mediates choles-In addition to the neutral bile biosynthesis pathway
terol efflux from cells, are each partly responsible fordiscussed above, an alternative or acidic pathway syn-
decreased cholesterol absorption. Furthermore, thethesizes predominantly chenodeoxycholic acid from
LXR/RXR heterodimer specifically regulates the expres-cholesterol (Schwarz et al., 1998). The rate-limiting step
sion of ABCA1, since neither LG268 nor T0901317 (anin this pathway is catalyzed by mitochondrial sterol 27-
LXR-specific agonist) can induce ABCA1 in LXRa/b dou-hydroxylase encoded by the CYP27 gene. Analogous to
ble knockout mice. This body of work implicates nuclearthe CYP7A1 gene, transcription of the CYP27 gene is
receptors as the key regulators for cholesterol catabo-repressed by hydrophobic bile acids and enhanced by
lism and efflux, and suggests that the cross talk betweencholestyramine treatment of animals, which reduces the
nuclear receptors may serve to regulate pathways ofbile acid pool size. If LRH-1 participates in the regulation
cholesterol and lipid homeostasis (Figure 1).of CYP27 in liver, then SHP could also mediate repres-
In the past few years, the perception of nuclear recep-sion of this gene in response to bile acids. Thus, SHP
tors as ligand-modulated transcription factors whosemay have a more global role than previously recognized,
primary role is to mediate the effects of endocrine sig-in the coordinated repression of bile biosynthetic genes.
nals has been altered by the discovery of a multitudeHow does SHP repress the activity of nuclear recep-
of orphan receptors that can respond to dietary compo-tors such as LRH-1? Multiple mechanisms have been
nents, products of intermediary metabolism, and xeno-proposed, such as inhibition of DNA binding, recruit-
biotic chemicals (Blumberg and Evans, 1998). The pres-ment of repressors, and interference with coactivator
ent work delineates the genetic hierarchy that regulatesbinding (Lee et al., 2000). Although the precise mecha-
cholesterol and bile acid homeostasis: LXR a/b governnism by which SHP inhibits LRH-1 activity is unknown,
the uptake of dietary cholesterol by controlling its intesti-it is unlikely to be inhibition of DNA binding (Goodwin
nal transporter, and the interactions among FXR, SHP,et al., 2000; Lu et al., 2000). Whether inhibition occurs
and LRH-1 form the basis for the coordinated regulationby recruitment of corepressors, as it has been shown
of cholesterol degradation and bile acid secretion. Infor DAX-1 and SF-1, or by competition with coactivators
macrophages and perhaps other tissues, expression ofneeds to be examined in future experiments.
PPARg, a target of known prescription drugs, estab-In addition to interacting with LRH-1, SHP binds other
lishes an additional layer of regulation of cholesterolnuclear receptors such as estrogen receptor and reti-
efflux and absorption while RXR participates at all sitesnoid X receptors (RXR) in ligand-dependent manner (Lee
as a partner of PPARg, LXR a/b, and FXR.et al., 2000). Although the physiological relevance of
As a complement to traditional cholesterol-loweringthese interactions is unknown, high estrogen levels are
drugs that focus on inhibition of endogenous synthesis,associated with bile acid dysregulation. For example,
the identification of this collection of nuclear receptors
intrahepatic cholestasis of pregnancy occurs in the third
that mediates cholesterol absorption, reverse transport,
trimester when estrogen levels are peaking, and is clini-
and degradation provides an unprecedented opportu-
cally manifested by pruritus and high serum bile acid nity to pharmacologically manipulate these natural cho-
levels. One potential molecular mechanism by which lesterol-controlling pathways. Each is a potentially inter-
cholestasis occurs in this disorder may involve seques- esting drug development target. RXR compounds have
tration of SHP to other promoters by the liganded estro- been shown to be effective insulin sensitizers as well
gen receptors. This would result in loss of repression as potent inhibitors of cholesterol absorption and bile
on the CYP7A1 gene, thereby allowing for unregulated acid synthesis in animals (Mukherjee et al., 1997). PPARg
synthesis of bile acids. ligands are already widely used in treatment of type II
Although expression of FXR in liver and intestine is diabetes and more recently show promise in animals
consistent with its functional role in bile acid homeosta- as inhibitors of atherosclerosis (Willson et al., 2000).
sis, its expression in the adrenal gland and kidney is an Synthetic LXR agonists may lower serum cholesterol
enigma (Forman et al., 1995). Synthesis of bile acids levels by decreasing intestinal absorption while pre-
occurs in the liver and excretion occurs through the venting hepatic accumulation. FXR activators may be
biliary system. If there are areas of overlap between the useful to treat disorders of bile acid metabolism. Al-
pathways of steroidogenesis and cholesterol catabo- though not yet identified, small molecules that regulate
lism in the adrenal gland, FXR might be expected to SHP and LRH-1 could be useful in cases of either hyper-
modulate the expression of involved genes. Future stud- cholesterolemia or cholestasis, though certainly much
ies aimed at investigating the function of FXR in these less is understood regarding the extent and specificity
of their regulation. In spite of the tinkering that may betissues and determining if the FXR/SHP transcriptional
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necessary to develop clinical weapons based on our
new knowledge, the fact that at least six nuclear recep-
tors regulate distinct aspects of cholesterol homeosta-
sis means that new drugs controlling their activity will
be discovered.
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